Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa

被引:49
作者
Hansen, GT
Zhao, XL
Drlica, K
Blondeau, JM
机构
[1] Publ Hlth Res Inst, Newark, NJ 07103 USA
[2] Royal Univ, Dept Clin Microbiol, Saskatoon, SK, Canada
[3] Royal Univ, Dept Pathol, Saskatoon, SK, Canada
关键词
ciprofloxacin; levofloxacin; MPC; mutant selection window;
D O I
10.1016/j.ijantimicag.2005.10.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The mutant prevention concentration (MPC) was determined by population analysis using six fluoroquinolone-susceptible isolates of pseudomonas aeruginosa applied to fluoroquinolone-containing agar plates. The MPCs were 3 mg/L and 9.5 mg/L for ciprofloxacin and levofloxacin, respectively. At high concentrations of either compound, single-step gyrA resistance mutants were recovered. Using a modified method for estimating the MPC, 15 1 clinical isolates were surveyed. Modal MPCs were 2 mg/L and 8 mg/L, respectively, for ciprofloxacin and levofloxacin. Thus, ciprofloxacin is three to four times more active than levofloxacin against resistant mutant subpopulations. For individual isolates, the MPC correlated poorly with the minimum inhibitory concentration (r(2)=0.41 and 0.39 for ciprofloxacin and levofloxacin., respectively). (c) 2005 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:120 / 124
页数:5
相关论文
共 26 条
[1]   Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV [J].
Akasaka, T ;
Onodera, Y ;
Tanaka, M ;
Sato, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (03) :530-536
[2]  
[Anonymous], QUINOLONE MICROBIOLO
[3]   Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in US hospitals [J].
Bhavnani, SM ;
Callen, WA ;
Forrest, A ;
Gilliland, KK ;
Collins, DA ;
Paladino, JA ;
Schentag, JJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (19) :1962-1970
[4]   Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae [J].
Blondeau, JM ;
Zhao, XL ;
Hansen, G ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (02) :433-438
[5]  
CRAIG WA, 2002, INFEC DIS T, V28, P1
[6]   Effect of fluoroquinolone concentration on selection of resistant mutants of Mycobacterium bovis BCG and Staphylococcus aureus [J].
Dong, YZ ;
Zhao, XL ;
Domagala, J ;
Drlica, K .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (07) :1756-1758
[7]   The mutant selection window and antimicrobial resistance [J].
Drlica, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :11-17
[8]   Fluoroquinolones: Action and resistance [J].
Drlica, K ;
Malik, M .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2003, 3 (03) :249-282
[9]   Antimicrobial resistance in European isolates of Pseudomonas aeruginosa [J].
Fluit, AC ;
Verhoef, J ;
Schmitz, FJ .
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2000, 19 (05) :370-374
[10]   Characterization of Pseudomonas aeruginosa isolates:: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999 [J].
Gales, AC ;
Jones, RN ;
Turnidge, J ;
Rennie, R ;
Ramphal, R .
CLINICAL INFECTIOUS DISEASES, 2001, 32 :S146-S155